Thrombolysis in very elderly people: Controlled comparison of SITS international stroke thrombolysis registry and virtual international stroke trials archive

BMJ (Online)

Volumn 341, Issue 7783, 2010, Pages 1144-

  Mishra, Nishant K ^a   Ahmed, Niaz ^b   Andersen, Grethe ^c   Egido, José A ^d   Lindsberg, Perttu J ^e   Ringleb, Peter A ^f   Wahlgren, Nils G ^b   Lees, Kennedy R ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c AARHUS UNIVERSITY HOSPITAL   (Denmark)

^d HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^e HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^f UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE;

AGE DISTRIBUTION; AGED; ARTICLE; BLOOD CLOT LYSIS; BRAIN ISCHEMIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; ELDERLY CARE; FEMALE; FIBRINOLYTIC THERAPY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; REGISTER; SCORING SYSTEM; STROKE; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; CEREBRAL HEMORRHAGE; CLINICAL TRIALS AS TOPIC; FIBRINOLYTIC AGENTS; HUMANS; INFUSIONS, INTRAVENOUS; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; REGISTRIES; STROKE; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME; YOUNG ADULT;

EID: 78649624539     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.c6046     Document Type: Article

References (67)

1. Generalized efficacy of t-PA for acute stroke. Subgroup analysis of the NINDS t-PA Stroke Trial. Stroke 1997;28:2119-25.
2. National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl JMed 1995;333:1581-7.
3. Hacke W, Kaste M, Bluhmki E, Brozman M, Davalos A, Guidetti D, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl JMed 2008;359:1317-29.
4. Lees KR, Bluhmki E, von Kummer R, Brott TG, Toni D, Grotta JC, et al. Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet 2010;375:1695-703.
5. Ahmed N, Wahlgren N, Grond M, Hennerici M, Lees KR, Mikulik R, et al. Implementation and outcome of thrombolysiswith alteplase 3-4.5 h after an acute stroke: an updated analysis from SITS-ISTR. Lancet Neurol 2010;9:866-74.
6. Bonita R, Anderson CS, Broad JB, Jamrozik KD, Stewart-Wynne EG, Anderson NE. Stroke incidence and case fatality in Australasia. A comparison of the Auckland and Perth population-based stroke registers. Stroke 1994;25:552-7.
7. Marini C, Baldassarre M, Russo T, De Santis F, Sacco S, Ciancarelli I, et al. Burden of first-ever ischemic stroke in the oldest old: evidence from a population-based study. Neurology 2004;62:77-81.
8. Di Carlo A, Baldereschi M, Gandolfo C, Candelise L, Ghetti A, Maggi S, et al. Stroke in an elderly population: incidence and impact on survival and daily function. Italian Longitudinal Study on Aging. Cerebrovasc Dis 2003;16:141-50.
9. Derex L, Nighoghossian N. Thrombolysis, stroke-unit admission and early rehabilitation in elderly patients. Nat Rev Neurol 2009;5:506-11.
10. Hacke W, Kaste M, Fieschi C, Toni D, Lesaffre E, von Kummer R, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. European Cooperative Acute Stroke Study (ECASS). JAMA 1995;274:1017-25.
11. Hacke W, Albers G, Al-Rawi Y, Bogousslavsky J, Davalos A, Eliasziw M, et al. The Desmoteplase in Acute Ischemic Stroke Trial (DIAS): a phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase. Stroke 2005;36:66-73.
12. Hacke W, Furlan AJ, Al-Rawi Y, Davalos A, Fiebach JB, Gruber F, et al. Intravenous desmoteplase in patients with acute ischaemic stroke selected by MRI perfusion-diffusion weighted imaging or perfusion CT (DIAS-2): a prospective, randomised, double-blind, placebo-controlled study. Lancet Neurol 2009;8:141-50.
13. Wahlgren N. Systemic thrombolysis in clinical practice:what havewe learned after the Safe Implementation of Thrombolysis in Stroke Monitoring Study? Cerebrovasc Dis 2009;27(suppl 1):168-76.
14. Lees KR, Ford GA, Muir KW, Ahmed N, Dyker AG, Atula S, et al. Thrombolytic therapy for acute stroke in the United Kingdom: experience from the safe implementation of thrombolysis in stroke (SITS) register. Q JMed 2008;101:863-9.
15. Ringleb PA, Schwark C, Kohrmann M, Kulkens S, Juttler E, Hacke W, et al. Thrombolytic therapy for acute ischaemic stroke in octogenarians: selection by magnetic resonance imaging improves safety but does not improve outcome. J Neurol Neurosurg Psychiatry 2007;78:690-3. (Pubitemid 46998836)
16. Committee for the Proprietary Medicinal Products. Summary information on a referral opinion following an arbitration persuant to article 29 of directive 2001/83/EC, for actilyse. EMEA, 2002 (No: CPMP/3346/02-EN). www.ema.europa.eu/ pdfs/human/referral/Actilyse/334602en.pdf.
17. Hacke W, Donnan G, Fieschi C, Kaste M, von Kummer R, Broderick JP, et al. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet 2004;363:768-74.
18. Heuschmann PU, Kolominsky-Rabas PL, Roether J, Misselwitz B, Lowitzsch K, Heidrich J, et al. Predictors of in-hospital mortality in patients with acute ischemic stroke treated with thrombolytic therapy. JAMA 2004;292:1831-8.
19. Bateman BT, Schumacher HC, Boden-Albala B, Berman MF, Mohr JP, Sacco RL, et al. Factors associated with in-hospital mortality after administration of thrombolysis in acute ischemic stroke patients: an analysis of the nationwide inpatient sample 1999 to 2002. Stroke 2006;37:440-6.
20. Engelter ST, Bonati LH, Lyrer PA. Intravenous thrombolysis in stroke patients of > or = 80 versus < 80 years of age - a systematic review across cohort studies. Age Ageing 2006;35:572-80.
21. Fonarow GC, Reeves MJ, Zhao X, Olson DM, Smith EE, Saver JL, et al. Age-related differences in characteristics, performance measures, treatment trends, and outcomes in patients with ischemic stroke. Circulation 2010;121:879-91.
22. Foerch C, Sitzer M, Steinmetz H, Neumann-Haefelin T. Future demographic trends decrease the proportion of ischemic stroke patients receiving thrombolytic therapy: a call to set-up therapeutic studies in the very old. Stroke 2009;40:1900-2.
23. Dunnell K. Ageing and mortality in the UK - national statistician's annual article on the population. Popul Trends 2008;134:6-23.
24. Europeans are living longer. Official website of European Union. http://europa.eu/abc/keyfigures/sizeandpopulation/older/index-en.htm
25. Ali M, Atula S, Bath PM, Grotta J, Hacke W, Lyden P, et al. Stroke outcome in clinical trial patients deriving from different countries. Stroke 2009;40:35-40.
26. Ali M, Bath PM, Curram J, Davis SM, Diener HC, Donnan GA, et al. The virtual international stroke trials archive. Stroke 2007;38:1905-10.
27. Wahlgren N, Ahmed N, Davalos A, Ford GA, Grond M, Hacke W, et al. Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study. Lancet 2007;369:275-82.
28. Wahlgren N, Ahmed N, Davalos A, Hacke W, Millan M, Muir K, et al. Thrombolysis with alteplase 3-4.5 h after acute ischaemic stroke (SITS-ISTR): an observational study. Lancet 2008;372:1303-9.
29. Chacon MR, Jensen MB, Sattin JA, Zivin JA. Neuroprotection in cerebral ischemia: emphasis on the SAINT trial. Curr Cardiol Rep 2008;10:37-42.
30. Quinn TJ, Dawson J, Walters M. Dr John Rankin; his life, legacy and the 50th anniversary of the Rankin stroke scale. Scott Med J 2008;53:44-7.
31. Internet Stroke Center at Washington University in St Louis. www.strokecenter.org/.
32. Lees KR, Zivin JA, Ashwood T, Davalos A, Davis SM, Diener HC, et al. NXY-059 for acute ischemic stroke. N Engl J Med 2006;354:588-600.
33. Lees KR, Davalos A, Davis SM, Diener HC, Grotta J, Lyden P, et al. Additional outcomes and subgroup analyses of NXY-059 for acute ischemic stroke in the SAINT I trial. Stroke 2006;37:2970-8.
34. Gray LJ, Bath PM, Collier T. Should stroke trials adjust functional outcome for baseline prognostic factors? Stroke 2009;40:888-94.
35. Saver JL, Yafeh B. Confirmation of tPA treatment effect by baseline severity-adjusted end point reanalysis of the NINDS-tPA stroke trials. Stroke 2007;38:414-6.
36. Mann J. tPA for acute stroke: balancing baseline imbalances. CMAJ 2002;166:1651-2; author reply 1652-3.
37. Committee for Proprietary Medicinal Products, London. Points to consider on clinical investigation of medicinal products for the treatment of acute stroke. European Agency for the Evaluation of Medicinal Products, Sep 2001 (No: CPMP/EWP/560/98). www.tga.gov.au/docs/pdf/euguide/ewp/056098en.pdf.
38. Saver JL, Gornbein J. Treatment effects for which shift or binary analyses are advantageous in acute stroke trials. Neurology 2009;72:1310-5.
39. Fedorov V, Mannino F, Zhang R. Consequences of dichotomization. Pharm Stat 2009;8:50-61.
40. Senn S, Julious S. Measurement in clinical trials: a neglected issue for statisticians? Stat Med 2009;28:3189-209.
41. Bluhmki E, Windeler J, Hacke W. [Neurological scales as endpoints in stroke studies. Aspects of statistical evaluation]. Nervenarzt 2000;71:797-801.
42. Savitz SI, Lew R, Bluhmki E, Hacke W, Fisher M. Shift analysis versus dichotomization of the modified Rankin scale outcome scores in the NINDS and ECASS-II trials. Stroke 2007;38:3205-12.
43. Saver JL. Novel end point analytic techniques and interpreting shifts across the entire range of outcome scales in acute stroke trials. Stroke 2007;38:3055-62.
44. Gameroff MJ. Using the proportional odds model for health-related outcomes: Why, when, and how with various SAS procedures. Statistics and data analysis. SUGI 30 Proceedings. Paper 205-30. www2.sas.com/proceedings/sugi30/ toc.html#st.
45. Scott SC, Goldberg MS, Mayo NE. Statistical assessment of ordinal outcomes in comparative studies. J Clin Epidemiol 1997;50:45-55.
46. Engelter ST, Reichhart M, Sekoranja L, Georgiadis D, Baumann A, Weder B, et al. Thrombolysis in stroke patients aged 80 years and older: Swiss survey of IV thrombolysis. Neurology 2005;65:1795-8.
47. Von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. BMJ 2007;335:806-8.
48. Mateen FJ, Buchan AM, Hill MD, CASES Investigators. Outcomes of thrombolysis for acute ischemic stroke in octogenarians versus nonagenarians. Stroke 2010;41:1833-5.
49. Lees KR, Bluhmki E, Toni D, von Kummer R. MJ, Brott TG, et al. Time dependent response to treatment with intravenous rtPA for stroke: an updated pooled analysis of ECASS, ATLANTIS and NINDS stroke trials. Stroke 2010;41:e200.
50. Bath PM, Gray LJ, Collier T, Pocock S, Carpenter J. Can we improve the statistical analysis of stroke trials? Statistical reanalysis of functional outcomes in stroke trials. Stroke 2007;38:1911-5.
51. Brown DL, Coffey CS. Stroke trials: a shift to shift analysis? Neurology 2009;72:1292-3.
52. Weimar C, Konig IR, Kraywinkel K, Ziegler A, Diener HC. Age and National Institutes of Health stroke scale score within 6 hours after onset are accurate predictors of outcome after cerebral ischemia: development and external validation of prognostic models. Stroke 2004;35:158-62.
53. Konig IR, Ziegler A, Bluhmki E, Hacke W, Bath PM, Sacco RL, et al. Predicting long-term outcome after acute ischemic stroke: a simple index works in patients from controlled clinical trials. Stroke 2008;39:1821-6.
54. Mishra NK, Lyden P, Grotta JC, Lees KR, for the VISTA Collaborators. Thrombolysis is associated with consistent functional improvement across baseline stroke severity. A comparison of outcomes in patients from the virtual international stroke trials archive (VISTA). Stroke 2010;41:2612-7.
55. Ahmed A, Mishra NK, Kobayashi A, Käll T-B, Ringleb P, Lees KR, et al. Improved outcomes after thrombolysis across baseline NIHSS scores 5-24: controlled comparison of the SITS international registry (SITS-ISTR) versus Virtual International Stroke Trials Archive (VISTA). European Stroke Conference, 2010. Cerebrovasc Dis 2010;29(suppl 2):1-341.www.esc-archive.eu/barcelona10/ bar-author-1.asp.
56. Wahlgren N, Ahmed N, Eriksson N, Aichner F, Bluhmki E, Davalos A, et al. Multivariable analysis of outcome predictors and adjustment of main outcome results to baseline data profile in randomized controlled trials: Safe Implementation of Thrombolysis in Stroke-MOnitoring STudy (SITS-MOST). Stroke 2008;39:3316-22.
57. Ford GA Ahmed N, Azevedo E, Grond M, Larrue V, Lindsberg P, et al. Intravenous alteplase for stroke in those older than 80 years old. Stroke 2010;41:2568-74.
58. Uyttenboogaart M, Schrijvers EM, Vroomen PC, De Keyser J, Luijckx GJ. Routine thrombolysis with intravenous tissue plasminogen activator in acute ischaemic stroke patients aged 80 years or older: a single centre experience. Age Ageing 2007;36:577-9.
59. Mishra NK, Diener H-C, Lyden PD, Bluhmki E, Lees KR, for the VIS TA Collaborators. Influence of age on outcome from thrombolysis in acute stroke: a controlled comparison in patients from the virtual international stroke trials archive (VISTA). Stroke 2010; Oct 28, epub ahead of print.
60. Poppe AY, Hill MD. Acute ischaemic stroke in patients aged 80 years and older: focus on the tolerability of thrombolytic agents. Drugs Aging 2008;25:95-103.
61. Vatankhah B, Dittmar MS, Fehm NP, Erban P, Ickenstein GW, Jakob W, et al. Thrombolysis for stroke in the elderly. J Thromb Thrombolysis 2005;20:5-10.
62. Sylaja PN, Cote R, Buchan AM, Hill MD. Thrombolysis in patients older than 80 years with acute ischaemic stroke: Canadian Alteplase for Stroke Effectiveness Study. J Neurol Neurosurg Psychiatry 2006;77:826-9.
63. Toni D, Lorenzano S, Agnelli G, Guidetti D, Orlandi G, Semplicini A, et al. Intravenous thrombolysis with rt-PA in acute ischemic stroke patients aged older than 80 years in Italy. Cerebrovasc Dis 2008;25:129-35.
64. Mateen FJ, Buchan AM, Hill MD. Outcomes of thrombolysis for acute ischemic stroke in octogenarians versus nonagenarians. Stroke 2010;41:1833-5.
65. Toni D, Lorenzano S. Intravenous thrombolysis with rt-PA in acute stroke patients aged >or=80 years. Int J Stroke 2009;4:21-2.
66. Sandercock P, Lindley R, Wardlaw J, Dennis M, Lewis S, Venables G, et al. The third international stroke trial (IST-3) of thrombolysis for acute ischaemic stroke. Trials 2008;9:37.
67. Sandercock P. Thrombolysis of patients >80: a different view. UK Stroke Forum, 2009. www.dcn.ed.ac.uk/ist3/Glasgow-UKCRN-Dec2009/Thrombolysis- for-over-80-UKSF-debate-dec-2009-sandercock.ppt.